Description
“Reta 20mg” refers to Retatrutide (LY3437943), a novel peptide under investigation. It is a triple hormone receptor agonist. It targets three key receptors: GIP, GLP-1, and glucagon . This triple agonist design sets it apart from existing therapies. This note provides an overview of its scientific background. It also covers clinical trial data and significant safety warnings.
Chemical Identity and Mechanism
Chemical Identity
Retatrutide is a 39-amino acid synthetic peptide. It is engineered from a GIP peptide backbone . The CAS number is not yet widely published. It has a half-life of approximately 6 days . This supports once-weekly subcutaneous administration .
Mechanism of Action
Retatrutide activates GIP, GLP-1, and glucagon receptors simultaneously . GLP-1 and GIP receptor agonism reduces appetite. It also improves insulin response . Glucagon receptor agonism increases energy expenditure. It also promotes fat metabolism . Consequently, this triple action may enhance efficacy. It goes beyond dual or single receptor agonists .
Clinical Trial Data
TRIUMPH Program (Obesity and T2DM)
The TRIUMPH program includes five positive phase 3 trials . TRIUMPH-1 (obesity) showed impressive weight loss. The highest dose achieved an average 28.3% weight loss at 80 weeks .
TRIUMPH-2 (T2DM) randomized 1,152 participants . The 12 mg dose achieved an average 20.8% weight loss (49.6 lbs) . A1C reduction reached up to 1.6% .
TRIUMPH-3 (severe obesity + CVD) enrolled 1,949 participants . The highest dose delivered an average 22.6% weight loss (55.8 lbs) . It also improved triglycerides, non-HDL cholesterol, and blood pressure .
TRANSCEND-T2D-1 (Type 2 Diabetes)
This phase 3 trial included 537 participants . Retatrutide achieved up to a 2% reduction in A1C . It also delivered an average 16.8% weight loss (36.6 lbs) . The safety profile was consistent with GLP-1 receptor agonists . Gastrointestinal events were the most common .
Preclinical Findings
A 2026 study demonstrated additional benefits. Retatrutide alleviates adipose tissue fibrosis . It does this via metabolic reprogramming. It also promotes tissue repair .
Severe Safety Concerns
Regulatory Warning: Liver Toxicity
A major warning has been issued. Victoria’s Chief Health Officer reported six acute liver toxicity cases . These cases were linked to unapproved “Reta 20mg” products. Clinical presentation suggests possible contaminants . Symptoms include jaundice, abdominal pain, and dark urine .
Case Report: Ketoacidosis
A case report documented severe non-diabetic ketoacidosis . A 20-year-old female received a supratherapeutic dose. She escalated from 10 mg to 20 mg to 30 mg. This dose substantially exceeded the maximum 12 mg studied in trials .
Gray Market Safety Concerns
A 2026 analysis examined Reddit user experiences . Among 13,589 users, 7,823 reported symptoms. These included appetite increase and fatigue. They also included nausea, insomnia, and elevated heart rate .
Legal and Regulatory Status
FDA Approval Status
Retatrutide remains investigational. It is not FDA-approved for human use. Lilly plans to submit for approval in early 2027 .
TGA and Australian Warnings
The TGA warns against importing unapproved peptides . These products pose significant health risks. They have not been assessed for safety or quality . Australians should not use these products .
Internal and External Links
Internal Resources
Visit our Research Chemical Library for related peptides. Explore our Guide to Peptide Hormones. Review our Safety Protocols and Regulatory Compliance FAQ.
External Resources
-
[MedRxiv]: Read the Reddit user safety analysis at MedRxiv.
-
[Department of Health, Victoria]: View the official health alert at Health Victoria.
-
[Diabetes.org]: Read the ADA press release at Diabetes.org.
-
[Drug Topics]: Read the TRIUMPH trial update at Drug Topics.
-
[RACGP]: Read the urgent warning at RACGP.
-
[ScienceDirect]: Access research articles at ScienceDirect.
Reviews
There are no reviews yet.